OBJECTIVE: The aim of this study was to determine the incidence of thrombocytosis and its possible impact on survival probability among women with locally advanced cervical carcinoma. METHODS: The database of 294 patients with Stages IIB-IVA cervical carcinoma without periaortic node metastasis who were treated withstandardized radiation therapy and concurrent hydroxyurea or misonidazole was analyzed. Pretreatment platelet counts were available for 291 patients who are the subject of this study. RESULTS:Thrombocytosis (platelet count >400 x 10(9)/liter) was present in 86 (29.6%) of the 291 patients. A multivariate Cox proportional hazards model showed that patients without extrapelvic disease and with thrombocytosis had a 55% greater chance of dying than those without thrombocytosis (relative risk = 1.55, 95% confidence interval 1.08-2.21). Patients with thrombocytosis had larger tumors and more frequently had bilateral parametrial involvement, tumor fixation to the sidewall, and positive pelvic lymph nodes than patients without thrombocytosis. Thrombocytosis was not found to be a prognostic factor in patients with positive pelvic nodes. However, in patients with negative pelvic nodes, the presence or absence of thrombocytosis was related to survival. CONCLUSION:Thrombocytosis is a frequent finding among patients with advanced cervical carcinoma and seems to be related to tumor burden. Among patients with locally advanced cervical carcinoma who had negative pelvic nodes, those with thrombocytosis had a poorer survival. Copyright 2000 Academic Press.
RCT Entities:
OBJECTIVE: The aim of this study was to determine the incidence of thrombocytosis and its possible impact on survival probability among women with locally advanced cervical carcinoma. METHODS: The database of 294 patients with Stages IIB-IVA cervical carcinoma without periaortic node metastasis who were treated with standardized radiation therapy and concurrent hydroxyurea or misonidazole was analyzed. Pretreatment platelet counts were available for 291 patients who are the subject of this study. RESULTS:Thrombocytosis (platelet count >400 x 10(9)/liter) was present in 86 (29.6%) of the 291 patients. A multivariate Cox proportional hazards model showed that patients without extrapelvic disease and with thrombocytosis had a 55% greater chance of dying than those without thrombocytosis (relative risk = 1.55, 95% confidence interval 1.08-2.21). Patients with thrombocytosis had larger tumors and more frequently had bilateral parametrial involvement, tumor fixation to the sidewall, and positive pelvic lymph nodes than patients without thrombocytosis. Thrombocytosis was not found to be a prognostic factor in patients with positive pelvic nodes. However, in patients with negative pelvic nodes, the presence or absence of thrombocytosis was related to survival. CONCLUSION:Thrombocytosis is a frequent finding among patients with advanced cervical carcinoma and seems to be related to tumor burden. Among patients with locally advanced cervical carcinoma who had negative pelvic nodes, those with thrombocytosis had a poorer survival. Copyright 2000 Academic Press.
Authors: Ismael Domínguez; Stefano Crippa; Sarah P Thayer; Yin P Hung; Cristina R Ferrone; Andrew L Warshaw; Carlos Fernández-Del Castillo Journal: World J Surg Date: 2008-06 Impact factor: 3.352
Authors: Nora T Kizer; Hatem Hatem; Elizabeth K Nugent; Gongfu Zhou; Kathleen Moore; Paul Heller; David G Mutch; Premal H Thaker Journal: Int J Gynecol Cancer Date: 2015-07 Impact factor: 3.437
Authors: Pavlos Msaouel; Anthony P Lam; Krishna Gundabolu; Grigorios Chrysofakis; Yiting Yu; Ioannis Mantzaris; Ellen Friedman; Amit Verma Journal: Haematologica Date: 2014-02-07 Impact factor: 9.941
Authors: Marc A Brockmann; Alf Giese; Kathrin Mueller; Finjap Janvier Kaba; Frank Lohr; Christel Weiss; Stefan Gottschalk; Ingo Nolte; Jan Leppert; Jochen Tuettenberg; Christoph Groden Journal: Neuro Oncol Date: 2007-05-15 Impact factor: 12.300
Authors: Marta Biedka; Roman Makarewicz; Ewa Kopczyńska; Andrzej Marszałek; Alina Goralewska; Hanna Kardymowicz Journal: Contemp Oncol (Pozn) Date: 2012-02-29